A Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Determine the Effects of 8 Weeks Treatment With Oral ZPL-3893787 (30 mg od x 56 Days) on Pruritus in Adult Subjects With Moderate to Severe Atopic Dermatitis

Trial Profile

A Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Determine the Effects of 8 Weeks Treatment With Oral ZPL-3893787 (30 mg od x 56 Days) on Pruritus in Adult Subjects With Moderate to Severe Atopic Dermatitis

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs ZPL 3893787 (Primary)
  • Indications Atopic dermatitis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Ziarco
  • Most Recent Events

    • 13 Jun 2016 According to Ziarco media release, primary endpoint (Change from baseline in Numerical Rating Scale (NRS) for Pruritus over 24 hrs) safety_issue: No time_frame: 8 weeks has been met.
    • 13 Jun 2016 According to Ziarco media release, results from this trial were presented at European Academy of Allergy and Clinical Immunology 35th Annual Congress 2016.
    • 13 Jun 2016 Results published in the Ziarco media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top